Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

Clinical trial NCT06222489 · RECRUITING

Trial details

NCT number: NCT06222489
Sponsor: The Netherlands Cancer Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Carcinoma Advanced Non-Small Cell Squamous Lung Cancer EGFR Gene Mutation

Start date: 2025-03-03
Primary completion: 2027-05-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.